Drug intelligence / Profile preview

NTQ6179

Development stage: Unknown
Lead developer: NorthSea Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

NTQ6179 is an orally administered small molecule somatostatin receptor type 2 (SSTR2) agonist being developed by Nanjing Chia Tai Tianqing Pharmaceutical and China Pharmaceutical University. It is designed for the treatment of acromegaly and neuroendocrine tumors (NETs). By selectively activating SSTR2, NTQ6179 aims to inhibit the secretion of growth hormone and other regulatory peptides. The drug is currently in Phase I clinical development in China, with a Phase Ia trial evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.

Targets

SSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on NTQ6179.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTQ6179.

Explore the full profile